Showing results (41-50 of 552) with videos related to
Sort By:
Pageof 56
Wiener Medizinische Wochenschrift (1946)|August 31, 1986
[Clinical picture of Parkinson disease]W BirkmayerJournal of Neural Transmission. Supplementum|January 1, 1978
Toxic delirium after L-dopa medicationW BirkmayerAktuelle Gerontologie|October 1, 1979
[Psychological problems of incurable patients in old age (author's transl)]W BirkmayerPharmacopsychiatry|May 1, 1988
Treatment of impaired cerebral function in psychogeriatric patients with memantine--results of a phase II double-blind studyL Ambrozi, W DanielczykNeuroscience Letters|June 16, 2000
Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndromeN Durany, R Zöchling, K W Boissl, et al.European Journal of Clinical Pharmacology|January 1, 1992
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinuedH Przuntek, D Welzel, E Blümner, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|January 1, 1996
Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO studyH Przuntek, D Welzel, M Gerlach, et al.Neurology|October 1, 1990
Right-left disorientation in dementia of the Alzheimer typeP Fischer, A Marterer, W DanielczykAnnals of Clinical and Laboratory Science|January 1, 1989
Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's diseaseW Birkmayer, G J BirkmayerActa Neurologica Scandinavica. Supplementum|January 1, 1989
Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH)G J Birkmayer, W BirkmayerPageof 56